Eli Lilly presents new EBGLYSS data from Phase 3 ADorable-1 pediatric atopic dermatitis study at Fall Clinical 2026

By Public Technologies
  • Lilly outlined 21 dermatology presentations scheduled for Oct. 8-11 at Fall Clinical 2026, with new data across EBGLYSS, Taltz, Zepbound.
  • EBGLYSS posters will focus on durable disease control, less frequent maintenance dosing, reduced reliance on topical treatments in moderate-to-severe atopic dermatitis.
  • TOGETHER-PsO analyses will assess tirzepatide added to ixekizumab in psoriasis with obesity, including biomarker readouts and cardiovascular risk factors.
  • BRAVE-AA-PEDS updates will present longer-term outcomes for Olumiant in adolescents with severe alopecia areata, supporting pediatric expansion efforts.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610050750PR_NEWS_USPR_____DE63096) on October 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.